Orchid Pharma today said it has received Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its Chennai facility.
The company has received the EIR from the US drug regulator on successful inspection closure.
According to the BSE filing, the regulator conducted the post-marketing adverse drug experience reporting inspection (PADE) at Nungambakkam, Chennai facility.
The company's stock closed 4.93% up on the BSE today.
The company has received the EIR from the US drug regulator on successful inspection closure.
According to the BSE filing, the regulator conducted the post-marketing adverse drug experience reporting inspection (PADE) at Nungambakkam, Chennai facility.
The company's stock closed 4.93% up on the BSE today.